Ana Catarina Menezes

Dr. Ana Catarina Menezes

National Human Genome Research Institute, Bethesda, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IMInês Patrunilho Efe Macário
Inês Patrunilho Efe Macário
HOHelena Oliveira
Helena Oliveira
AMAna Catarina Menezes
Ana Catarina Menezes
SVSonia P. M. Ventura
Sonia P. M. Ventura
Joana Luisa PereiraJoana Luisa Pereira
Joana Luisa Pereira
FGFernando J. M. Gonçalves
Fernando J. M. Gonçalves
The tailor-made character of deep eutectic solvents (DES) turns them very attractive to be used in several applications, including in health-related areas such as pharmaceutical, nutraceutical, and cosmetic industries. However, although DES has been touted as “green” solvents, several works proved that their potential toxicity should not be neglected. Using the premise of DES applicability in the cosmetic and pharmaceutical sectors, we chose two cell lines to work as a skin model (keratinocytes HaCaT and tumor melanocytes MNT-1), to assess DES cytotoxicity. The effect of three different hydrogen bond acceptors (HBA) ([Chol]Cl, [N1111]Cl and [N4444]Cl) and three different hydrogen bond donors (HBD) (hexanoic and butanoic acid, ethylene glycol, 1-propanol and urea) were evaluated through a common viability assay (MTT assay). Results were promising since [Chol]Cl and [N1111]Cl- based DES showed good biocompatibility for the tested cells. [N4444]Cl-based DES, however, showed cytotoxicity for both cell lines, with the HBA being the driver of the toxicity. Interestingly, some compounds increased cell viability in the HaCaT cell line, namely [Chol]Cl, ethylene glycol, hexanoic acid, urea, and all [Chol]Cl and [N1111]Cl-based DES and should be considered as targets for future studies. These results highlight their possible use in cosmetic or pharmaceutical formulations.

1 August 2019 in Stem Cell Reports
Verified
Journal Article
Open access
JMJuan Bautista Menendez-Gonzalez
Juan Bautista Menendez-Gonzalez
MVMilica Vukovic
Milica Vukovic
AAAli Abdelfattah
Ali Abdelfattah
LSLubaid Saleh
Lubaid Saleh
AAAlhomidi Almotiri
Alhomidi Almotiri
NRNeil P Rodrigues
Neil P Rodrigues
Subversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia (AML). Using a conditional mouse model where zinc-finger TF Gata2 was deleted specifically in hematopoietic cells, we show that knockout of Gata2 leads to rapid and complete cell-autonomous loss of adult hematopoietic stem cells. By using short hairpin RNAi to target GATA2, we also identify a requirement for GATA2 in human HSPCs. In Meis1a/Hoxa9-driven AML, deletion of Gata2 impedes maintenance and self-renewal of LSCs. Ablation of Gata2 enforces an LSC-specific program of enhanced apoptosis, exemplified by attenuation of anti-apoptotic factor BCL2, and re-instigation of myeloid differentiation--which is characteristically blocked in AML. Thus, GATA2 acts as a critical regulator of normal and leukemic stem cells and mediates transcriptional networks that may be exploited therapeutically to target key facets of LSC behavior in AML.

1 July 2016 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
AMAna Catarina Menezes
Ana Catarina Menezes
PCPatrícia Mazureki Campos
Patrícia Mazureki Campos
CECarla Euletério
Carla Euletério
Sandra SimõesSandra Simões
Sandra Simões
FPFabíola Silva Garcia Praça
Fabíola Silva Garcia Praça
AAAndreia Ascenso
Andreia Ascenso

8 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMona Mohammadhosseini
Mona Mohammadhosseini
TETrevor Enright
Trevor Enright
ADAdam S DuVall
Adam S DuVall
ACAlex Chitsazan
Alex Chitsazan
HLHsin-Yun Lin
Hsin-Yun Lin
AAAnupriya Agarwal
Anupriya Agarwal
Familial platelet disorder (FPD) is associated with germline RUNX1 mutations, establishing a preleukemic state and increasing the risk of developing leukemia. Currently, there are no intervention strategies to prevent leukemia progression. Single-cell RNA sequencing ( n = 10) combined with functional analysis of samples from patients with RUNX1 -FPD ( n > 75) revealed that FPD hematopoietic stem and progenitor cells (HSPCs) displayed increased myeloid differentiation and suppressed megakaryopoiesis because of increased activation of prosurvival and inflammatory pathways. Bone marrow from patients with RUNX1 -FPD contained an elevated cytokine milieu, exerting chronic inflammatory stress on HSPCs. RUNX1 -FPD HSPCs were myeloid biased, had increased self-renewal, and were resistant to inflammation-mediated exhaustion. The bone marrow from patients with RUNX1 -FPD showed high transcript and protein expression of CD74 at the preleukemic stage compared with that of healthy controls, which remained high upon patient transformation into leukemia. Further, CD74-mediated signaling was exaggerated in RUNX1 -FPD HSPCs compared with healthy controls, leading to the activation of mTOR and JAK/STAT pathways with increased cytokine production. Genetic and pharmacological targeting of CD74 with ISO-1 and its downstream targets JAK1/2 and mTOR reversed RUNX1 -FPD differentiation defects in vitro and in vivo and reduced inflammation. Our results highlight that inflammation is an early event in RUNX1 -FPD pathogenesis, and CD74 signaling is one of the drivers of this inflammation. The repurposing of JAK1/2i (ruxolitinib) and mTORi (sirolimus) and promoting the advancement of CD74 inhibitors in clinical settings as an early intervention strategy would be beneficial to improve the phenotype of patients with RUNX1 -FPD and prevent myeloid progression.

28 February 2020 in Materials
Verified
Journal Article
Open access
PDF file
Ricardo J.B. PintoRicardo J.B. Pinto
Ricardo J.B. Pinto
DBDaniela S. C. Bispo
Daniela S. C. Bispo
Carla VilelaCarla Vilela
Carla Vilela
Alexandre BotasAlexandre Botas
Alexandre Botas
Rute FerreiraRute Ferreira
Rute Ferreira
Carmen FreireCarmen Freire
Carmen Freire
Gold nanoparticles (AuNPs) are one of the most studied nanosystems with great potential for biomedical applications, including cancer therapy. Although some gold-based systems have been described, the use of green and faster methods that allow the control of their properties is of prime importance. Thus, the present study reports a one-minute microwave-assisted synthesis of fucoidan-coated AuNPs with controllable size and high antitumoral activity. The NPs were synthesized using a fucoidan-enriched fraction extracted from Fucus vesiculosus, as the reducing and capping agent. The ensuing monodispersed and spherical NPs exhibit tiny diameters between 5.8 and 13.4 nm for concentrations of fucoidan between 0.5 and 0.05% (w/v), respectively, as excellent colloidal stability in distinct solutions and culture media. Furthermore, the NPs present antitumoral activity against three human tumor cell lines (MNT-1, HepG2, and MG-63), and flow cytometry in combination with dark-field imaging confirmed the cellular uptake of NPs by MG-63 cell line.

30 April 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
AMAna Catarina Menezes
Ana Catarina Menezes
RJRachel Jones
Rachel Jones
ASAlina Shrestha
Alina Shrestha
RNRachael Nicholson
Rachael Nicholson
ALAdam Leckenby
Adam Leckenby
Alex TonksAlex Tonks
Alex Tonks
RUNX3 is a transcription factor dysregulated in acute myeloid leukemia (AML). However, its role in normal myeloid development and leukemia is poorly understood. Here we investigate RUNX3 expression in both settings and the impact of its dysregulation on myelopoiesis. We found that RUNX3 mRNA expression was stable during hematopoiesis but decreased with granulocytic differentiation. In AML, RUNX3 mRNA was overexpressed in many disease subtypes, but downregulated in AML with core binding factor abnormalities, such as RUNX1::ETO. Overexpression of RUNX3 in human hematopoietic stem and progenitor cells (HSPC) inhibited myeloid differentiation, particularly of the granulocytic lineage. Proliferation and myeloid colony formation were also inhibited. Conversely, RUNX3 knockdown did not impact the myeloid growth and development of human HSPC. Overexpression of RUNX3 in the context of RUNX1::ETO did not rescue the RUNX1::ETO-mediated block in differentiation. RNA-sequencing showed that RUNX3 overexpression downregulates key developmental genes, such as KIT and RUNX1, while upregulating lymphoid genes, such as KLRB1 and TBX21. Overall, these data show that increased RUNX3 expression observed in AML could contribute to the developmental arrest characteristic of this disease, possibly by driving a competing transcriptional program favoring a lymphoid fate.